Institution
Castle Hill Hospital
Healthcare•Cottingham, United Kingdom•
About: Castle Hill Hospital is a healthcare organization based out in Cottingham, United Kingdom. It is known for research contribution in the topics: Heart failure & Population. The organization has 1302 authors who have published 1655 publications receiving 59663 citations.
Papers published on a yearly basis
Papers
More filters
••
14 Apr 2005TL;DR: Cardiac resynchronization has been shown to reduce symptoms and improve left ventricular function in patients with heart failure due to systolic dysfunction and cardiac dyssynchrony.
Abstract: background Cardiac resynchronization reduces symptoms and improves left ventricular function in many patients with heart failure due to left ventricular systolic dysfunction and cardiac dyssynchrony We evaluated its effects on morbidity and mortality methods Patients with New York Heart Association class III or IV heart failure due to left ventricular systolic dysfunction and cardiac dyssynchrony who were receiving standard pharmacologic therapy were randomly assigned to receive medical therapy alone or with cardiac resynchronization The primary end point was the time to death from any cause or an unplanned hospitalization for a major cardiovascular event The principal secondary end point was death from any cause results A total of 813 patients were enrolled and followed for a mean of 294 months The primary end point was reached by 159 patients in the cardiac-resynchronization group, as compared with 224 patients in the medical-therapy group (39 percent vs 55 percent; hazard ratio, 063; 95 percent confidence interval, 051 to 077; P<0001) There were 82 deaths in the cardiac-resynchronization group, as compared with 120 in the medical-therapy group (20 percent vs 30 percent; hazard ratio 064; 95 percent confidence interval, 048 to 085; P<0002) As compared with medical therapy, cardiac resynchronization reduced the interventricular mechanical delay, the end-systolic volume index, and the area of the mitral regurgitant jet; increased the left ventricular ejection fraction; and improved symptoms and the quality of life (P<001 for all comparisons) conclusions In patients with heart failure and cardiac dyssynchrony, cardiac resynchronization improves symptoms and the quality of life and reduces complications and the risk of death These benefits are in addition to those afforded by standard pharmacologic therapy The implantation of a cardiac-resynchronization device should routinely be considered in such patients
5,493 citations
••
TL;DR: Results from this randomised trial provide convincing and consistent evidence that short-course preoperative radiotherapy is an effective treatment for patients with operable rectal cancer.
1,296 citations
••
TL;DR: In this article, the authors compared placebo with perindopril, 4 mg/day in patients with a diagnosis of heart failure, treated with diuretics and an echocardiogram suggesting diastolic dysfunction and excluding substantial LV systolic dysfunction or valve disease.
Abstract: Aims Many patients who receive a diagnosis of heart failure have neither a low left ventricular (LV) ejection fraction nor valve disease. Few substantial randomized controlled trials have been conducted in this population, none has focussed on patients with evidence of diastolic dysfunction and none has shown clear benefit on symptoms, morbidity, or mortality. Methods and results This was a randomized double-blind trial, comparing placebo with perindopril, 4 mg/ day in patients aged � 70 years with a diagnosis of heart failure, treated with diuretics and an echocardiogram suggesting diastolic dysfunction and excluding substantial LV systolic dysfunction or valve disease. The primary endpoint was a composite of all-cause mortality and unplanned heart failure related hospitalization with a minimum follow-up of 1 year. A total of 850 patients were randomized. Their mean age was 76 (SD 5) years and 55% were women. Median follow-up was 2.1 (IQR 1.5–2.8) years. Enrolment and event rates were lower than anticipated, reducing the power of the study to show a difference in the primary endpoint to 35%. Many patients withdrew from perindopril (28%) and placebo (26%) after 1 year and started taking open-label ACE-inhibitors. Overall, 107 patients assigned to placebo and 100 assigned to perindopril reached the primary endpoint (HR 0.919: 95% CI 0.700–1.208; P ¼ 0.545). By 1 year, reductions in the primary outcome (HR 0.692: 95% CI 0.474–1.010; P ¼ 0.055) and hospitalization for heart failure (HR 0.628: 95% CI 0.408–0.966; P ¼ 0.033) were observed and functional class (P , 0.030) and 6-min corridor walk distance (P ¼ 0.011) had improved in those assigned to perindopril. Conclusion Uncertainty remains about the effects of perindopril on long-term morbidity and mortality in this clinical setting since this study had insufficient power for its primary endpoint. However, improved symptoms and exercise capacity and fewer hospitalizations for heart failure in the first year were observed on perindopril, during which most patients were on assigned therapy, suggesting that it may be of benefit in this patient population.
1,230 citations
••
TL;DR: In rectal cancer, the plane of surgery achieved is an important prognostic factor for local recurrence, and both a negative circumferential resection margin and a superior plane of Surgery achieved were associated with lowLocal recurrence rates.
897 citations
••
TL;DR: The prevalence of chronic heart failure rises with increasing age, from <1% in those below 65 years of age to > 5% in the elderly in general and is a major cause of morbidity and mortality in older people.
Abstract: Background: The prevalence of chronic heart failure (CHF) rises with increasing age, from 5% in those over 65 years of age and is a major cause of morbidity and mortality in older people. Recent European guidelines point to a major deficiency in our knowledge of how to treat diastolic chronic heart failure, and a lack of information on treatment for heart failure in the elderly in general. Aims: The aims of this trial are to assess the potential benefits of the ACE inhibitor perindopril to treat chronic heart failure in elderly people, in the absence of any major left ventricular systolic dysfunction. Subjects: One thousand people over the age of 70 years will be recruited into this study. Evidence of chronic heart failure will be confirmed by clinical criteria and echocardiography. Methods: Once a diagnosis of chronic heart failure has been confirmed, the patient will receive either perindopril or placebo in addition to their usual treatment. Death, and unplanned heart failure related hospitalisations, are the primary outcomes. Quality of life, as measured by the Guyatt questionnaire will be assessed at the beginning of the study and at 1 year. Sub-studies of this trial include a 6-min walking test and more detailed evaluation of ventricular function (as assessed by echocardiography). Both parameters will be measured at 8 weeks and 1 year, and analysed against baseline data. Cognitive function in this group of patients will also be evaluated at baseline and 1 year. This trial is due to report in the year 2001. (C) 1999 European Society of Cardiology. All rights reserved.
778 citations
Authors
Showing all 1307 results
Name | H-index | Papers | Citations |
---|---|---|---|
John G.F. Cleland | 137 | 1172 | 110227 |
Ara Darzi | 123 | 1613 | 64907 |
Paul W. Armstrong | 114 | 811 | 79389 |
Nick Freemantle | 89 | 592 | 40742 |
Alexander C. Ford | 79 | 488 | 22186 |
Michael J. Kerin | 71 | 454 | 21243 |
John D. Horowitz | 66 | 456 | 23952 |
Andrew L. Clark | 65 | 426 | 15108 |
Laurence J. O'Toole | 58 | 190 | 12474 |
Richard J. Schilling | 54 | 321 | 11232 |
Norman J. Maitland | 52 | 214 | 21276 |
John R. T. Monson | 49 | 141 | 10713 |
Denis O'Mahony | 49 | 215 | 15708 |
Michael B. Bennett | 47 | 279 | 8480 |
Thibaud Damy | 46 | 213 | 7314 |